Form 4: Vaxcyte COO Jim Wassil Executes Stock Option and Sells Shares Under 10b5-1 Plan

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan on November 1, 2024.

Summary

• On November 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc. [PCVX], exercised stock options to acquire 8,000 shares of common stock at a price of $2.42 per share.
• Simultaneously, Wassil sold a total of 7,999 shares of Vaxcyte common stock in a series of transactions.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 1, 2024.
• The sales prices ranged from $105.75 to $108.93 per share.
• Following these transactions, Wassil directly owns 205,695 shares of Vaxcyte common stock and 26,638 derivative securities (stock options).

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The transactions appear to be part of a pre-planned strategy, so there's no immediate cause for alarm or excitement.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to sell shares over time, which helps avoid accusations of trading on inside information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small volume of shares sold.

Key Dates